Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Emmaus Life Sciences, Inc.MYND · Entity 205 | Chief Executive Officer | December 12, 2018 | December 14, 2018 |
| Telemynd, Inc.NONE · Entity 155932 | Director · Chief Executive Officer | June 25, 2019 | July 05, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Emmaus Life Sciences, Inc.
Report date December 12, 2018 · Filed December 14, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| EMPLOYEE STOCK OPTION (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $1.28 · Expires 2028-12-12 | Direct | 400,000 |
Reported balance
After 2018-12-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-12-12 · Grant · Acquired 400,000 · Balance 400,000 F1: On December 12, 2018, the Reporting Person was granted an option to purchase 400,000 shares of common stock. Options to purchase 200,000 of such shares were issued under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan, pursuant to an Employment Agreement, dated as of December 12, 2018, by and between the Company and the Reporting Person. 50,000 of the 400,000 options vested on the grant date, with the remainder vesting upon the satisfaction of performance targets or time-based vesting schedules specified in the Employment Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 12, 2018, the Reporting Person was granted an option to purchase 400,000 shares of common stock. Options to purchase 200,000 of such shares were issued under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan, pursuant to an Employment Agreement, dated as of December 12, 2018, by and between the Company and the Reporting Person. 50,000 of the 400,000 options vested on the grant date, with the remainder vesting upon the satisfaction of performance targets or time-based vesting schedules specified in the Employment Agreement.
Telemynd, Inc.
Report date June 25, 2019 · Filed July 05, 2019
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 12, 2018 Filed Dec 14, 2018 21:55 UTC | Emmaus Life Sciences, Inc. MYND · Entity 205 | GrantEMPLOYEE STOCK OPTION (right to purchase) · Derivative | 400,000 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001615774-18-014475 · s114740_form4.xml · derivative · entry 1 Herguth Patrick · CIK 0001353199 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2028-12-12 F1 · shares: On December 12, 2018, the Reporting Person was granted an option to purchase 400,000 shares of common stock. Options to purchase 200,000 of such shares were issued under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan, pursuant to an Employment Agreement, dated as of December 12, 2018, by and between the Company and the Reporting Person. 50,000 of the 400,000 options vested on the grant date, with the remainder vesting upon the satisfaction of performance targets or time-based vesting schedules specified in the Employment Agreement. F1 · derivative.expiration_date: On December 12, 2018, the Reporting Person was granted an option to purchase 400,000 shares of common stock. Options to purchase 200,000 of such shares were issued under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan, pursuant to an Employment Agreement, dated as of December 12, 2018, by and between the Company and the Reporting Person. 50,000 of the 400,000 options vested on the grant date, with the remainder vesting upon the satisfaction of performance targets or time-based vesting schedules specified in the Employment Agreement. F1 · balance_after: On December 12, 2018, the Reporting Person was granted an option to purchase 400,000 shares of common stock. Options to purchase 200,000 of such shares were issued under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan, pursuant to an Employment Agreement, dated as of December 12, 2018, by and between the Company and the Reporting Person. 50,000 of the 400,000 options vested on the grant date, with the remainder vesting upon the satisfaction of performance targets or time-based vesting schedules specified in the Employment Agreement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.